Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia.
作者信息
Stankovic Tatjana
机构信息
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
出版信息
Haematologica. 2019 Dec;104(12):2332-2334. doi: 10.3324/haematol.2019.230896.
Abstract
摘要
相似文献
1
Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia.正常细胞与白血病细胞之间p53功能的微调：一种治疗慢性淋巴细胞白血病的新策略。
Haematologica. 2019 Dec;104(12):2332-2334. doi: 10.3324/haematol.2019.230896.
2
Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.全面的单核苷酸多态性研究支持MDM2在具有野生型p53功能的慢性淋巴细胞白血病中的作用。
J Clin Oncol. 2008 May 10;26(14):2244-5. doi: 10.1200/JCO.2007.15.7818.
3
Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.Nutlin-3 下调原代 B 慢性淋巴细胞白血病细胞中癌基因 TCL1 的表达。
Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.
4
Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中的癌基因拷贝数改变
Turk J Haematol. 2019 Aug 2;36(3):220-221. doi: 10.4274/tjh.galenos.2019.2019.0179. Epub 2019 May 23.
5
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.MDM2基因单核苷酸多态性309与B细胞慢性淋巴细胞白血病的不良预后相关。
J Clin Oncol. 2008 May 10;26(14):2252-7. doi: 10.1200/JCO.2007.11.5212.
6
Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.慢性淋巴细胞白血病中 p53 肿瘤抑制通路基因分析。
DNA Cell Biol. 2012 May;31(5):777-82. doi: 10.1089/dna.2011.1314. Epub 2011 Nov 2.
7
p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.p53通路基因单核苷酸多态性与慢性淋巴细胞白血病
Cancer Genet Cytogenet. 2007 Nov;179(1):36-44. doi: 10.1016/j.cancergencyto.2007.07.013.
8
MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.MDM2 启动子 SNP309 与慢性淋巴细胞白血病的易感性增加相关，并与中国 CLL 患者的 MDM2 mRNA 表达相关。
Int J Cancer. 2012 May 1;130(9):2054-61. doi: 10.1002/ijc.26222. Epub 2011 Aug 9.
9
Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.将B细胞慢性淋巴细胞白血病（B-CLL）细胞暴露于nutlin-3会诱导出一种特征性的基因表达谱，这与nutlin-3介导的细胞毒性相关。
Curr Cancer Drug Targets. 2009 Jun;9(4):510-8. doi: 10.2174/156800909788486777.
10
Investigation of Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病病例中癌基因拷贝数改变的研究
Turk J Haematol. 2019 May 3;36(2):126-127. doi: 10.4274/tjh.galenos.2018.2018.0270. Epub 2018 Oct 16.
本文引用的文献
1
Inhibition of p53 inhibitors: progress, challenges and perspectives.p53 抑制剂的抑制：进展、挑战和展望。
J Mol Cell Biol. 2019 Jul 19;11(7):586-599. doi: 10.1093/jmcb/mjz075.
2
p53 modifications: exquisite decorations of the powerful guardian.p53 修饰：强大守护者的精致装饰。
J Mol Cell Biol. 2019 Jul 19;11(7):564-577. doi: 10.1093/jmcb/mjz060.
3
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.非遗传毒性 MDM2 抑制物选择性诱导慢性淋巴细胞白血病细胞中促凋亡的 p53 基因特征。
Haematologica. 2019 Dec;104(12):2429-2442. doi: 10.3324/haematol.2018.206631. Epub 2019 Apr 19.
4
Chronic Lymphocytic Leukemia: Diagnosis and Treatment.慢性淋巴细胞白血病：诊断与治疗。
Mayo Clin Proc. 2018 May;93(5):651-664. doi: 10.1016/j.mayocp.2018.03.002.
5
Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.慢性淋巴细胞白血病和套细胞淋巴瘤：遗传与微环境相互作用的交汇点。
Blood. 2018 May 24;131(21):2283-2296. doi: 10.1182/blood-2017-10-764373. Epub 2018 Apr 17.
6
MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?人肝细胞癌中MDM2与p53的相互作用：Nutlins的作用及新的治疗选择是什么？
J Clin Med. 2018 Mar 27;7(4):64. doi: 10.3390/jcm7040064.
7
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.伊布替尼单药治疗初治和复发/难治性慢性淋巴细胞白血病：5 年经验。
Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.
8
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.正在临床评估中的 MDM2/X 抑制剂：用于血液系统恶性肿瘤和儿科癌症治疗的前景。
J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5.
9
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.靶向MDM2-p53蛋白-蛋白相互作用用于新型癌症治疗：进展与挑战
Cold Spring Harb Perspect Med. 2017 May 1;7(5):a026245. doi: 10.1101/cshperspect.a026245.
10
Exploiting the p53 Pathway for Therapy.利用p53信号通路进行治疗。
Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a026310. doi: 10.1101/cshperspect.a026310.
Zotero 插件